Header Logo

Connection

Erica Erlank to Antimalarials

This is a "connection" page, showing publications Erica Erlank has written about Antimalarials.
Connection Strength

0,739
  1. The anticancer human mTOR inhibitor sapanisertib potently inhibits multiple Plasmodium kinases and life cycle stages. Sci Transl Med. 2022 10 19; 14(667):eabo7219.
    View in: PubMed
    Score: 0,204
  2. Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite Plasmodium falciparum and Optimization Efforts. J Med Chem. 2021 02 25; 64(4):2291-2309.
    View in: PubMed
    Score: 0,182
  3. Multistage and transmission-blocking targeted antimalarials discovered from the open-source MMV Pandemic Response Box. Nat Commun. 2021 01 11; 12(1):269.
    View in: PubMed
    Score: 0,181
  4. Effectiveness of reactive focal mass drug administration and reactive focal vector control to reduce malaria transmission in the low malaria-endemic setting of Namibia: a cluster-randomised controlled, open-label, two-by-two factorial design trial. Lancet. 2020 04 25; 395(10233):1361-1373.
    View in: PubMed
    Score: 0,172
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.